Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Safety and efficacy of subcutaneous tanezumab in patients with knee or hip osteoarthritis.

Birbara C, Dabezies EJ Jr, Burr AM, Fountaine RJ, Smith MD, Brown MT, West CR, Arends RH, Verburg KM.

J Pain Res. 2018 Jan 8;11:151-164. doi: 10.2147/JPR.S135257. eCollection 2018.

2.

Intra-articular hylastan versus steroid for knee osteoarthritis.

Housman L, Arden N, Schnitzer TJ, Birbara C, Conrozier T, Skrepnik N, Wei N, Bockow B, Waddell D, Tahir H, Hammond A, Goupille P, Sanson BJ, Elkins C, Bailleul F.

Knee Surg Sports Traumatol Arthrosc. 2014 Jul;22(7):1684-92. doi: 10.1007/s00167-013-2438-7. Epub 2013 Feb 16.

PMID:
23417236
3.

Efficacy and safety of tanezumab in the treatment of chronic low back pain.

Katz N, Borenstein DG, Birbara C, Bramson C, Nemeth MA, Smith MD, Brown MT.

Pain. 2011 Oct;152(10):2248-58. doi: 10.1016/j.pain.2011.05.003. Epub 2011 Jun 21.

PMID:
21696889
4.

Long-term open-label study of tanezumab for moderate to severe osteoarthritic knee pain.

Schnitzer TJ, Lane NE, Birbara C, Smith MD, Simpson SL, Brown MT.

Osteoarthritis Cartilage. 2011 Jun;19(6):639-46. doi: 10.1016/j.joca.2011.01.009. Epub 2011 Jan 18.

5.

Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT).

Mease PJ, Ory P, Sharp JT, Ritchlin CT, Van den Bosch F, Wellborne F, Birbara C, Thomson GT, Perdok RJ, Medich J, Wong RL, Gladman DD.

Ann Rheum Dis. 2009 May;68(5):702-9. doi: 10.1136/ard.2008.092767. Epub 2008 Aug 6.

6.

Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2.

van der Heijde D, Kavanaugh A, Gladman DD, Antoni C, Krueger GG, Guzzo C, Zhou B, Dooley LT, de Vlam K, Geusens P, Birbara C, Halter D, Beutler A.

Arthritis Rheum. 2007 Aug;56(8):2698-707.

7.
8.

Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial.

Kavanaugh A, Krueger GG, Beutler A, Guzzo C, Zhou B, Dooley LT, Mease PJ, Gladman DD, de Vlam K, Geusens PP, Birbara C, Halter DG, Antoni C; IMPACT 2 Study Group.

Ann Rheum Dis. 2007 Apr;66(4):498-505. Epub 2006 Nov 17.

9.

Treatment of rheumatoid arthritis patients with abatacept and methotrexate significantly improved health-related quality of life.

Emery P, Kosinski M, Li T, Martin M, Williams GR, Becker JC, Blaisdell B, Ware JE Jr, Birbara C, Russell AS.

J Rheumatol. 2006 Apr;33(4):681-9. Epub 2006 Mar 1.

PMID:
16568505
10.

Efficacy and safety of rofecoxib 12.5 mg and celecoxib 200 mg in two similarly designed osteoarthritis studies.

Birbara C, Ruoff G, Sheldon E, Valenzuela C, Rodgers A, Petruschke RA, Chang DJ, Tershakovec AM.

Curr Med Res Opin. 2006 Jan;22(1):199-210.

PMID:
16393445
11.

Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.

Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, Birbara C, Box J, Natarajan K, Nuamah I, Li T, Aranda R, Hagerty DT, Dougados M.

N Engl J Med. 2005 Sep 15;353(11):1114-23. Erratum in: N Engl J Med. 2005 Nov 24;353(21):2311.

12.

Frequency, predictors, and economic impact of upward dose adjustment of infliximab in managed care patients with rheumatoid arthritis.

Ollendorf DA, Massarotti E, Birbara C, Burgess SM.

J Manag Care Pharm. 2005 Jun;11(5):383-93.

13.

Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial.

Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, Zhou B, Dooley LT, Kavanaugh A; IMPACT 2 Trial Investigators.

Ann Rheum Dis. 2005 Aug;64(8):1150-7. Epub 2005 Jan 27.

14.

Rabeprazole for the prevention of recurrent erosive or ulcerative gastro-oesophageal reflux disease. Rabeprazole Study Group.

Birbara C, Breiter J, Perdomo C, Hahne W.

Eur J Gastroenterol Hepatol. 2000 Aug;12(8):889-97.

PMID:
10958216

Supplemental Content

Loading ...
Support Center